A phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma.

被引：0
|
作者：
Smrekar, M
Buller, RE
Haba, P
Visser, C
Rose, PG
机构：
[1] Hillcrest Hosp, Mayfield Hts, OH USA
[2] GlaxoSmithKline, Philadelphia, PA USA
[3] Metrohlth Med Ctr, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5147
引用
收藏
页码：485S / 485S
页数：1
相关论文
共 50 条
  • [31] A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients
    Homesley, H
    Benigno, B
    Williams, J
    Vaccarello, L
    GYNECOLOGIC ONCOLOGY, 2002, 87 (02) : 171 - 177
  • [32] Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma
    Hess, V
    Verrill, MW
    Bomphray, CC
    Vaughan, MM
    Allen, M
    Gore, ME
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 638 - 642
  • [33] Topotecan (T) and carboplatin (C) in the treatment of platinum sensitive relapsed ovarian cancer (ROC): Results of a multicenter phase I/II study.
    Koensgen, D.
    Belau, A.
    Klare, P.
    Steck, T.
    Camara, O.
    Sommer, H.
    Oskay-Oezcelik, G.
    Coumbos, A.
    Lichtenegger, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 277S - 277S
  • [34] PHASE I/II STUDY OF CARBOPLATIN AND PRALATREXATE IN PATIENTS WITH RECURRENT PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
    del Carmen, M.
    Campos, S.
    Krasner, C.
    Berlin, S.
    Supko, J.
    Atkinson, T.
    Birrer, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 419 - 420
  • [35] Phase I clinical trial of weekly combined topotecan and irinotecan
    Lokich, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (04): : 336 - 340
  • [36] A Phase I trial of weekly docetaxel and topotecan for solid tumors
    Lim, Wan Teck
    Baggstrom, Maria Q.
    Read, William
    Fracasso, Paula M.
    Govindan, Ramaswamy
    ACTA ONCOLOGICA, 2008, 47 (02) : 311 - 315
  • [37] Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial
    Shawky, Hanan
    Tawfik, Hesham
    Hewidy, Medhat
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2014, 26 (03) : 139 - 145
  • [38] Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer
    Chelariu-Raicu, Anca
    Levenback, Charles
    Slomovitz, Brian
    Wolf, Judith
    Bodurka, Diane C.
    Kavanagh, John J.
    Morrison, Christopher
    Gershenson, David
    Coleman, Robert
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1768 - 1774
  • [39] Phase II prospective study of weekly topotecan and bevacizumab in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
    McGonigle, K. F.
    Muntz, H. G.
    Vuky, J.
    Paley, P. J.
    Veljovich, D. S.
    Gray, H. J.
    Malpass, T. W.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S145 - S145
  • [40] A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma
    Kose, MF
    Sufliarsky, J
    Beslija, S
    Saip, P
    Tulunay, G
    Krejcy, K
    Minarik, T
    Fitzthum, E
    Hayden, A
    Melemed, A
    GYNECOLOGIC ONCOLOGY, 2005, 96 (02) : 374 - 380
12345